Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications

  title={Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications},
  author={Michael Hallek and Linda K. Wanders and S S Strohmeyer and Bertold Emmerich},
  journal={Annals of Hematology},
SummaryThymidine kinase (TK) is a cellular enzyme which is involved in a “salvage pathway” of DNA synthesis. It is activated in the G1/S phase of the cell cycle, and its activity has been shown to correlate with the proliferative activity of tumor cells. Additionally, certain viruses are able to induce cellular TK production and activity. Clinical studies have reported elevated serum TK levels in a variety of neoplasias. The majority of these studies concerned hematologic malignancies. TK seems… 

Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma.

  • B. Madewell
  • Medicine, Biology
    Journal of veterinary internal medicine
  • 2004
Thymidine kinase seems to be a useful marker in non-Hodgkin's lymphoma, where it correlates with clinical staging and provides marked prognostic information on (progression-free) survival.

Thymidine kinase 1 through the ages: a comprehensive review

Compared to other proliferation markers, TK1 levels during S phase more accurately determine the rate of DNA synthesis in actively dividing tumors, and is potentially more advantageous than current biomarkers.

Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia.

The results indicated the importance of TK activity as a prognostic factor in patients with CLL and compared its activity with that of other prognostic and predictive factors.

Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases.

The present review will focus on the recent results concerning TK1's S phase-correlated expression, increased serum levels of Tk1 in patients with malignancies and the relevance for veterinary and comparative oncology.

Changes of serum thymidine kinase in children with acute leukemia.

The study showed that the elevation of TK serum levels during follow-up was a helpful marker for the recognition of an early stage of relapse and in some cases occurred as early as one month before the appearance of clinical signs.

Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.

Although the performance of serum TK for diagnosis and therapy monitoring of advanced lung cancer was poor, it has a promising prognostic relevance which will have to be further validated.

Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity--evaluation of a new, fully automated non-radiometric assay.

The Liaison TK assay showed high precision, high sensitivity and a good correlation to the TK REA, which provides valuable clinical information in the treatment and management of canine LEUK and ML, with a potential to be further validated in human trials.

Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker

There are differences in the specific activities and the subunit compositions of STK1 in hematological malignancies compared with breast and prostate cancer, and this fact has several important implications for the use ofSTK1 as a tumor biomarker.

Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors

It was showed that serum TK1 concentration could be a predictive marker of IGHV mutational status, and might be applied for the assessment of prognosis in patients with CLL.



Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia

When different variables and combinations of variables were studied in order to define their capacity for discriminating between progressive and indolent CLL, S‐TK activity and PI proved to be powerful indications.

Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia

It is concluded that S‐TK could be used as a prognostic marker for the individual CLL patient and seems to be useful for longitudinal follow‐up studies of disease status, both in indolent disease and in progressive disease during treatment.

Activity of serum thymidine kinase in non-Hodgkin lymphoma: Relationship to other prognostic factors

The results indicate that TK might be a worthful parameter to estimate progression and response to therapy of NHL and correlated better with Binet stages than blood sedimentation rate.

Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma.

It is suggested that peripheral blood TK1 isozyme is a useful independent biochemical marker for a subgroup of NHL who respond poorly to current therapy and thus require new therapeutic approaches.

The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.

It is concluded that s-dTk could be used both as a prognostic marker and to monitor the effect of therapy in NHL patients.

Application of an in vitro assay for serum thymidine kinase: Results on viral disease and malignancies in humans

The TK activity in sera from patients with both mononucleosis and tumor disease was characterized by electrophoresis and by its ability to utilize cytidine triphosphate as the phosphate donor, and showed that the serum TK has the same properties as the human cytosolar TK1, except in connection with varicella.

Serum deoxythymidine kinase as a progressive marker of hematological malignancy.

The results suggest that high levels of s-dTK in hematological malignancy may reflect the extent of disease and that this activity may be derived from proliferating leukemic cells.

Thymidine kinase in breast cancer.

Serum thymidine kinase reflects stage of disease in breast cancer and serial thymazine kinase levels in patients with systemic breast cancer reflected response to systemic therapy.

Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis

The respective pretreatment prognostic impacts of the following markers were evaluated in 125 patients with small cell lung cancer (SCLC): lactic dehydrogenase (LDH), serum thymidine kinase (S‐TK),